Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Minimal Change Disease (MCD) is a significant cause of nephrotic syndrome in adults, often presenting with more severe features than in children.
• Rituximab (RTX), a B-cell depleting therapy, is established for treating frequently relapsing nephrotic syndrome in pediatric patients.
• Limited data exists on the efficacy of RTX for MCD in adult populations.

Purpose of the Study:

• To evaluate the efficacy and safety of Rituximab (RTX) in adult patients with biopsy-proven Minimal Change Disease (MCD).
• To assess RTX's impact on proteinuria, renal function, and B-cell depletion in this patient group.

Main Methods:

• A case series involving 6 adult patients (45-73 years) with biopsy-proven MCD.
• Treatment administered included 4 weekly doses of RTX (375 mg/m²).
• Outcomes measured included proteinuria, serum creatinine levels, CD19 lymphocyte counts, and adverse events.

Main Results:

• Proteinuria significantly decreased from a median of 11.2 g/24h to 0.6 g/24h at 6 months, and 0.4 g/24h in longer follow-ups.
• Serum creatinine levels improved from a median of 1.95 mg/dl to 0.88 mg/dl.
• Five patients achieved complete renal remission, and one experienced a 75% reduction in proteinuria. RTX successfully depleted CD19+ B-cells in all patients for at least 6 months with no significant adverse events.

Conclusions:

• Rituximab demonstrates remarkable efficacy in the treatment of adult Minimal Change Disease.
• RTX offers a viable alternative for both induction therapy and managing recurrent forms of MCD, particularly in patients at high risk for corticosteroid side effects.
• Further randomized trials are necessary to establish optimal clinical guidelines for RTX use in adult MCD patients.